AI + iHTS™ Display
Highest affinity and unprecedented diversity —
Maximize your R&D success in the AI era.
We transform your reference antibody into 10 experimentally validated candidates with world leading binding affinities in just 2 months.
Maximum affinities possible in the industry with the broadest sequence diversity to strengthen your IP moat
The AI + iHTS™ DBTL Cycle
An exhaustive, non-cherry-picked approach to discover the absolute best variants for your target.
How to Start Collaborating
A streamlined, frictionless process from sequence to validated candidates.
1
We can be reached through email or phone and will get back to you right away. Once we understand your needs, we will be able to generate solutions for you. After that we get started.
2
This is the equivalent of running thousands of experiments in parallel to find the best characteristics for your mab. We call this our Design Build Test Learn loop approach, which is an approach we validated with many leading companies to precision engineer the best possible final sequences.
3
These are all patent-distinct sequences + complete BLI data.
Why Trust Us
Built for pharma and biotech leaders who demand the best data
The best of both worlds
AI/precision engineering + Physical production + BLI testing — actual data delivered
Patent-Safe Space
10,000+ novel variants while preserving epitope.
Superior Performance
On average, our campaigns generate dramatically more coverage and affinity gains
Complete Data Package
Full BLI sensorgrams + affinity values for all 10 final sequences
Unique Platform
Only Fidelis integrates AI language models + AlphaFold3 + automatic iHTS™
Proven Speed
Reliable 2-month delivery with updates.
Our Track Record
Our team has worked successfully with all major pharmaceutical, biotechnology companies, and academic institutions on antibody development, as well as academic institutions.
